Related Experiment Video
Updated: Jul 2, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
The evolving role of catumaxomab in gastric cancer
Florian Lordick1, Katja Ott, Jürgen Weitz
1University of Heidelberg, National Center for Tumour Diseases, Department of Medical Oncology, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany. florian.lordick@med.uni-heidelberg.de
Background:
Gastric cancer is a condition with a high medical need. Even after R0 resection the rate of peritoneal and other distant site recurrences is high. Novel therapeutic approaches include trifunctional antibodies (trAb) that recruit and activate different types of immune effector cells at the tumour site. The trAb catumaxomab has dual antigen specificity for epithelial cell adhesion molecule and CD3 and binds to Fcgamma-receptor-positive accessory cells. Intraperitoneal administration of catumaxomab in patients with malignant ascites due to epithelial cancer significantly increased puncture-free survival.
Objective:
To review the mode of action of catumaxomab and describe clinical data regarding the emerging role of catumaxomab in the treatment of patients with gastric cancer. A summary of completed and ongoing clinical trials including patients with gastric cancer is given.
Conclusion:
Catumaxomab is a promising approach in the treatment of patients with gastric cancer.
